Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / HOXA9



This biomarker is also known as:
  • ABD-B,
  • homeobox protein Hox-1G,
  • homeodomain protein HOXA9,
  • P31269,
  • homeo box A9,
  • HOX1G,
  • HOX1.7,
  • Homeobox protein Hox-1G,
  • homeobox A9,
  • HOX1,
  • homeobox protein Hox-A9,

View in BioMuta


HOXA9 is a sequence-specific transcription factor. It is a member of the homeobox gene family. These transcription factors are spatially and temporally regulated during embryonic development. HOXA9 is part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression, morphogenesis, and differentiation. Read-through transcription exists between this gene and the upstream homeobox A10 (HOXA10) gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…

Head & neck, NOS


Phase: One
QA State: Curated


HOXA9 and NID2 have been identified as novel differentially methylated genes in oral squamous cell carcinoma. These genes were also shown to have significantly higher methylation levels in tumor than normal oral mucosa, as seen by ROC analysis of head and neck squamous cell carcinoma samples.

Performance Comment

HOXA9 and NID2 are promising oral squamous cell carcinoma biomarkers that should be studied on tissue, saliva and serum from larger cohorts. HOXA9 and NID2 were chosen for further study because they were the only candidate genes that had an AUC value equal to or higher than 0.75, and 100% specificity and sensitivity higher than 70%.



Phase: Two
QA State: Under Review


DNA methylation of HOXA9 has been found to be associated with ovarian cancer.

Performance Comment

HOXA9 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. HOXA9 was not in the group of 13 selected for further validation.



Phase: One
QA State: Under Review


Performance Comment


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.